Company news
Immutep Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
October 3, 2024
Immutep receives A$3.6 million French R&D Tax Incentive
September 23, 2024
New Positive Efficacy Data for Efti in Head and Neck Cancer
September 15, 2024
S&P DJI Announces September 2024 Quarterly Rebalance
September 6, 2024
Appendix 4E & 2024 Full Year Statutory Accounts
August 30, 2024
TACTI-003 data selected for oral presentation at ESMO 2024
August 20, 2024
First Participant Dosed in Phase I Study of IMP761
August 13, 2024
Successful Meeting with FDA on Phase III Design in NSCLC
July 21, 2024
Regulatory Clearance received for Phase 1 trial of IMP761
July 16, 2024
Webcast to discuss data presented at ESMO Plenary Session
July 11, 2024
Positive results in TACTI-003 for 1L HNSCC cohort B patients
July 11, 2024
Webcast slides for new Efti clinical data in 1st line HNSCC
June 26, 2024
Positive topline results from ph2b in head & neck cancer
June 26, 2024
Immutep completes underwritten retail entitlement offer
June 24, 2024
Immutep completes institutional pro-rata offer & placement
June 4, 2024
Immutep announces Ph 3 clinical trial collaboration with MSD
June 3, 2024
Immutep Capital Raising Presentation
June 2, 2024
A$100 million fully underwritten equity raising
June 2, 2024
AIPAC-003 safety lead-in data presented at ESMO Breast 2024
May 15, 2024
Positive initial data in phase 2 Soft Tissue Sarcoma trial
May 1, 2024
Positive preliminary topline results from TACTI-003 Cohort B
April 23, 2024
CHDR to conduct first-in-human phase 1 trial of IMP761
April 17, 2024
First Clinical Data announced from 90mg Dosing of Efti
March 5, 2024
PEI provides constructive feedback for ph3 lung cancer trial
December 20, 2023
Immutep receives A$2.6 million French R&D Tax Incentive
December 6, 2023
Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
November 8, 2023
Lead-in phase completed for ph2/3 trial in Breast Cancer
November 5, 2023
New Biomarker Data from TACTI-002 trial in 1st line NSCLC
November 2, 2023
Immutep reports promising data from INSIGHT-003 trial
October 23, 2023
Webcast slides for new Efti clinical data in 1st line NSCLC
October 22, 2023
Excellent Overall Survival in Non-Small Cell Lung Cancer
October 22, 2023
Immutep announces publication of ESMO 2023 abstracts
October 15, 2023
Commercial Scale Manufacturing of Efti for Clinical Trials
September 20, 2023
Appendix 4E & 2023 Full Year Statutory Accounts
August 29, 2023
Immutep receives positive scientific advice from EMA
August 1, 2023
1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
July 27, 2023
US patent granted for Efti with PD-1 pathway inhibitor
June 27, 2023
Immutep granted US patent for IMP761 agonist LAG-3 antibody
June 20, 2023
A$80 million fully underwritten equity raising
May 30, 2023
Charles River Laboratories to run IMP761 Toxicology Study
May 28, 2023
Publication of Abstracts for ASCO 2023 Annual Meeting
May 25, 2023
1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
May 24, 2023
Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
May 23, 2023
Excellent initial Overall Survival Benefit in 1st line NSCLC
May 16, 2023
FDA supportive of Efti registrational trial in lung cancer
May 15, 2023
Approval to start Efti & Bavencio trial in urothelial cancer
April 30, 2023
Immutep to announce new TACTI-002 data at ASCO 2023
April 26, 2023
Response to ASX Aware Query
April 18, 2023
Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
April 16, 2023
Positive Final Data in 2nd Line Metastatic NSCLC Patients
March 31, 2023
Decks
The 5 newest of 112 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 30 slides · Aug 20, 2026
- Investor Presentation (February 2026)
Investor deck · 39 slides · Feb 20, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 27, 2025
- Investor Presentation (October 2025)
Investor deck · 37 slides · October 2025
- Jefferies Global Healthcare Conference 2025
Conference · 40 slides · Jun 2, 2025